News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,386 Results
Type
Article (45570)
Company Profile (334)
Press Release (680481)
Multimedia
Podcasts (95)
Webinars (15)
Section
Business (208593)
Career Advice (2031)
Deals (36062)
Drug Delivery (110)
Drug Development (84563)
Employer Resources (175)
FDA (16841)
Job Trends (15170)
News (354213)
Policy (33476)
Tag
Academia (2719)
Academic (1)
Accelerated approval (12)
Adcomms (30)
Allergies (99)
Alliances (51130)
ALS (115)
Alzheimer's disease (1514)
Antibody-drug conjugate (ADC) (174)
Approvals (16812)
Artificial intelligence (332)
Autoimmune disease (33)
Automation (19)
Bankruptcy (368)
Best Places to Work (11872)
BIOSECURE Act (22)
Biosimilars (129)
Biotechnology (240)
Bladder cancer (100)
Brain cancer (39)
Breast cancer (385)
Cancer (3025)
Cardiovascular disease (238)
Career advice (1699)
Career pathing (30)
CAR-T (209)
CDC (32)
Cell therapy (567)
Cervical cancer (23)
Clinical research (69421)
Collaboration (1087)
Company closure (3)
Compensation (708)
Complete response letters (31)
COVID-19 (2726)
CRISPR (66)
C-suite (348)
Cystic fibrosis (119)
Data (3061)
Decentralized trials (2)
Denatured (25)
Depression (70)
Diabetes (365)
Diagnostics (6568)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (148)
Drug pricing (132)
Drug shortages (31)
Duchenne muscular dystrophy (134)
Earnings (88513)
Editorial (45)
Employer branding (21)
Employer resources (151)
Events (117204)
Executive appointments (872)
FDA (18535)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (977)
Gene editing (144)
Generative AI (25)
Gene therapy (435)
GLP-1 (862)
Government (4637)
Grass and pollen (4)
Guidances (181)
Healthcare (19409)
HIV (43)
Huntington's disease (31)
IgA nephropathy (40)
Immunology and inflammation (169)
Immuno-oncology (10)
Indications (40)
Infectious disease (2904)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (123)
Interviews (314)
IPO (16867)
IRA (46)
Job creations (3705)
Job search strategy (1439)
Kidney cancer (14)
Labor market (52)
Layoffs (535)
Leadership (19)
Legal (8047)
Liver cancer (82)
Longevity (12)
Lung cancer (425)
Lymphoma (216)
Machine learning (11)
Management (59)
Manufacturing (412)
MASH (96)
Medical device (13804)
Medtech (13809)
Mergers & acquisitions (19931)
Metabolic disorders (915)
Multiple sclerosis (99)
NASH (18)
Neurodegenerative disease (132)
Neuropsychiatric disorders (38)
Neuroscience (2236)
NextGen: Class of 2025 (6750)
Non-profit (4603)
Now hiring (47)
Obesity (464)
Opinion (236)
Ovarian cancer (104)
Pain (117)
Pancreatic cancer (121)
Parkinson's disease (196)
Partnered (22)
Patents (310)
Patient recruitment (171)
Peanut (52)
People (58945)
Pharmaceutical (76)
Pharmacy benefit managers (21)
Phase I (21699)
Phase II (30527)
Phase III (22755)
Pipeline (1682)
Policy (216)
Postmarket research (2730)
Preclinical (9279)
Press Release (69)
Prostate cancer (150)
Psychedelics (46)
Radiopharmaceuticals (272)
Rare diseases (510)
Real estate (6034)
Recruiting (68)
Regulatory (23386)
Reports (50)
Research institute (2456)
Resumes & cover letters (353)
Rett syndrome (10)
RNA editing (9)
RSV (52)
Schizophrenia (94)
Series A (166)
Series B (116)
Service/supplier (12)
Sickle cell disease (66)
Special edition (21)
Spinal muscular atrophy (158)
Sponsored (33)
Startups (3740)
State (2)
Stomach cancer (17)
Supply chain (77)
Tariffs (58)
The Weekly (68)
Vaccines (826)
Venture capital (55)
Weight loss (296)
Women's health (49)
Worklife (17)
Date
Today (96)
Last 7 days (370)
Last 30 days (1902)
Last 365 days (32241)
2025 (17450)
2024 (36417)
2023 (41153)
2022 (52435)
2021 (56957)
2020 (55227)
2019 (47786)
2018 (36075)
2017 (33187)
2016 (32633)
2015 (38663)
2014 (32336)
2013 (27383)
2012 (29513)
2011 (30202)
2010 (28405)
Location
Africa (753)
Alabama (61)
Alaska (7)
Arizona (250)
Arkansas (13)
Asia (39860)
Australia (6588)
California (7594)
Canada (2383)
China (710)
Colorado (330)
Connecticut (327)
Delaware (194)
Europe (88030)
Florida (1147)
Georgia (257)
Hawaii (1)
Idaho (60)
Illinois (659)
India (28)
Indiana (367)
Iowa (17)
Japan (236)
Kansas (112)
Kentucky (30)
Louisiana (14)
Maine (64)
Maryland (1045)
Massachusetts (5745)
Michigan (247)
Minnesota (460)
Mississippi (3)
Missouri (98)
Montana (30)
Nebraska (25)
Nevada (81)
New Hampshire (71)
New Jersey (2121)
New Mexico (30)
New York (2139)
North Carolina (1156)
North Dakota (10)
Northern California (3327)
Ohio (240)
Oklahoma (17)
Oregon (37)
Pennsylvania (1642)
Puerto Rico (17)
Rhode Island (36)
South America (1130)
South Carolina (35)
South Dakota (1)
Southern California (2822)
Tennessee (128)
Texas (1154)
United States (28341)
Utah (224)
Virginia (189)
Washington D.C. (75)
Washington State (645)
West Virginia (4)
Wisconsin (70)
726,386 Results for "intra cellular therapies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
April 2, 2025
·
10 min read
Mergers & acquisitions
Johnson & Johnson Makes Major Neuro Play With $14.6B Intra-Cellular Buyout
Among Intra-Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for major depressive disorder.
January 13, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
January 13, 2025
·
20 min read
Neuroscience
Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar
Intra-Cellular submitted its application to the FDA for Caplyta’s approval in major depressive disorder, potentially opening up an additional $1 billion in sales. Still, the stock remains “cheap,” according to Jefferies analysts.
December 3, 2024
·
4 min read
·
Annalee Armstrong
Press Releases
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
February 24, 2025
·
14 min read
Press Releases
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition
April 2, 2025
·
4 min read
Business
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
Intra-Cellular Therapies, Inc. today announced the promotion of Michael Halstead, J.D. to the position of President.
March 19, 2024
·
2 min read
Pharm Country
Intra-Cellular Therapies to Participate in Two Upcoming May 2024 Investor Conferences
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that it will participate in two upcoming investor conferences.
May 8, 2024
·
1 min read
Pharm Country
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Intra-Cellular Therapies, Inc. today announced that it will participate in three upcoming investor conferences.
March 6, 2024
·
1 min read
Pharm Country
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
Intra-Cellular Therapies, Inc. highlights data presentations at the American Society of Clinical Psychopharmacology Annual Meeting being held in Miami, May 28 - 31, 2024.
May 23, 2024
·
9 min read
1 of 72,639
Next
